https://from.publifarm.com/pubblicazioni/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/ropeginterferon-phase-2-randomized-study-in-low-risk-polycythemia-vera-5-year-drug-survival-and-efficacy-outcomes/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/cerebral-autoregulation-in-traumatic-brain-injury-ultra-low-frequency-pressure-reactivity-index-and-intracranial-pressure-across-age-groups/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/mesenchymal-stromal-cells-for-traumatic-brain-injury-matrix-a-study-protocol-for-a-multicenter-double-blind-randomised-placebo-controlled-phase-ii-trial/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/survival-expectation-after-thrombosis-and-overt-myelofibrosis-in-essential-thrombocythemia-and-prefibrotic-myelofibrosis-a-multistate-model-approach/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/evaluation-and-application-of-ultra-low-resolution-pressure-reactivity-index-in-moderate-or-severe-traumatic-brain-injury/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/paediatric-porto-sinusoidal-vascular-disease-two-different-clinical-phenotypes-with-subtle-histological-differences/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/clonal-hematopoiesis-in-myeloproliferative-neoplasms-confers-a-predisposition-to-both-thrombosis-and-cancer/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/one-year-mortality-in-covid-19-is-associated-with-patients-comorbidities-rather-than-pneumonia-severity/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/polycythemia-vera-2024-update-on-diagnosis-risk-stratification-and-management/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/abo-blood-group-type-and-risk-of-venous-thrombosis-in-essential-thrombocythemia/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/outcome-of-129-pregnancies-in-polycythemia-vera-patients-a-report-of-the-european-leukemianet/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/evaluation-and-application-of-ultra-low-frequency-pressure-reactivity-index-in-pediatric-traumatic-brain-injury-patients/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/clinical-frailty-scale-as-a-predictor-of-outcome-in-elderly-patients-affected-by-moderate-or-severe-traumatic-brain-injury/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/liver-transplantation-in-patients-with-portal-vein-thrombosis-revisiting-outcomes-according-to-surgical-techniques/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/mri-evidence-of-olfactory-system-alterations-in-patients-with-covid-19-and-neurological-symptoms/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/increased-prevalence-of-autoimmune-thyroid-disease-after-covid-19-a-single-center-prospective-study/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/red-cell-distribution-width-rdw-is-correlated-to-time-of-oxygen-desaturation-90-and-length-of-sleep-apneas-in-patients-with-sleep-disorder-breathing-sdb-and-acute-heart-failure-with-preserved-ej/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/brain-diffusion-alterations-in-patients-with-covid-19-pathology-and-neurological-manifestations/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/the-international-consensus-classification-of-myeloid-neoplasms-and-acute-leukemias-myeloproliferative-neoplasms/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/splenomegaly-in-patients-with-primary-or-secondary-myelofibrosis-who-are-candidates-for-allogeneic-hematopoietic-cell-transplantation-a-position-paper-on-behalf-of-the-chronic-malignancies-working-pa/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/markers-of-blood-brain-barrier-disruption-increase-early-and-persistently-in-covid-19-patients-with-neurological-manifestations/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/determinants-of-early-triage-for-hospitalization-in-myeloproliferative-neoplasm-mpn-patients-with-covid-19/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/frequency-characteristics-and-outcome-of-patients-with-covid-19-pneumonia-and-silent-hypoxemia-at-admission-a-severity-matched-analysis/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/increased-risk-of-thrombosis-in-jak2-v617f-positive-patients-with-primary-myelofibrosis-and-interaction-of-the-mutation-with-the-ipss-score/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/breakthrough-infections-in-mpn-covid-vaccinated-patients/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/prediction-of-thrombosis-in-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis-a-study-on-1258-patients/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/perspective-pivotal-translational-hematology-and-therapeutic-insights-in-chronic-myeloid-hematopoietic-stem-cell-malignancies/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/site-specific-venous-thrombosis-in-essential-thrombocythemia-impact-on-subsequent-vascular-events-and-survival/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/impediments-to-heart-transplantation-in-adults-with-melasmt-tl1m-3243ag-cardiomyopathy/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/international-consensus-classification-of-myeloid-neoplasms-and-acute-leukemias-integrating-morphologic-clinical-and-genomic-data/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/adherence-of-ticagrelor-in-real-world-patients-with-acute-coronary-syndrome-the-ad-hoc-study/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/1-5-million-platelet-count-limit-at-essential-thrombocythemia-diagnosis-correlations-and-relevance-to-vascular-events/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/superb-microvascular-imaging-smi-compared-with-color-doppler-ultrasound-for-the-assessment-of-hepatic-artery-in-pediatric-liver-transplants-a-feasibility-study/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/cerebral-microbleeds-assessment-and-quantification-in-covid-19-patients-with-neurological-manifestations/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/a-randomized-phase-3-trial-of-interferon-%ce%b1-vs-hydroxyurea-in-polycythemia-vera-and-essential-thrombocythemia/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/association-between-inhibitors-of-the-renin-angiotensin-system-and-lung-function-in-elderly-patients-recovered-from-severe-covid-19/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/appropriate-management-of-polycythaemia-vera-with-cytoreductive-drug-therapy-european-leukemianet-2021-recommendations/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/usefulness-of-curb-65-pneumonia-severity-index-and-mulbsta-in-predicting-covid-19-mortality/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/neutrophil-to-lymphocyte-ratio-is-a-novel-predictor-of-venous-thrombosis-in-polycythemia-vera/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/thrombosis-in-myeloproliferative-neoplasms-during-cytoreductive-and-antithrombotic-drug-treatment/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/deciphering-the-individual-contribution-of-absolute-neutrophil-and-monocyte-counts-to-thrombosis-risk-in-polycythemia-vera-and-essential-thrombocythemia/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/impact-of-ruxolitinib-on-survival-of-patients-with-myelofibrosis-in-the-real-world-update-of-the-ernest-study/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/second-versus-first-wave-of-covid-19-in-patients-with-mpn/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/liver-transplantation-in-patients-with-non-neoplastic-portal-vein-thrombosis-20-years-of-experience-in-a-single-center/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/jak2v617f-variant-allele-frequency-50-identifies-patients-with-polycythemia-vera-at-high-risk-for-venous-thrombosis/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/antecedent-use-of-renin-angiotensin-system-inhibitors-is-associated-with-reduced-mortality-in-elderly-hypertensive-covid-19-patients/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/cerebral-venous-thrombosis-and-myeloproliferative-neoplasms-a-three-center-study-of-74-consecutive-cases/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/pre-transplant-alpha-fetoprotein-25-5-and-its-dynamic-on-waitlist-are-predictors-of-hcc-recurrence-after-liver-transplantation-for-patients-meeting-milan-criteria/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/philadelphia-negative-myeloproliferative-neoplasms-around-the-covid-19-pandemic/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/direct-oral-anticoagulants-for-myeloproliferative-neoplasms-results-from-an-international-study-on-442-patients/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/bl-01-an-fc-bearing-tetravalent-cd20-x-cd5-bispecific-antibody-redirects-multiple-immune-cells-to-kill-tumors-in-vitro-and-in-vivo/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/unmet-clinical-needs-in-the-management-of-calr-mutated-essential-thrombocythaemia-a-consensus-based-proposal-from-the-european-leukemianet/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/polycythemia-vera-historical-oversights-diagnostic-details-and-therapeutic-views/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/illustrated-state-of-the-art-capsules-of-the-isth-2020-congress/ 2025-02-18T09:46:09+00:00 https://from.publifarm.com/pubblicazioni/association-between-sleep-disordered-breathing-neurocognitive-impairment-and-diastolic-function-in-acute-heart-failure-patients-an-insight-after-the-vulnerable-phase-of-the-hospitalization/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/identification-of-human-sars-cov-2-monoclonal-antibodies-from-convalescent-patients-using-ebv-immortalization/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/long-term-follow-up-of-recovered-mpn-patients-with-covid-19/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/extreme-thrombocytosis-in-low-risk-essential-thrombocythemia-retrospective-review-of-vascular-events-and-treatment-strategies/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/covid-19-and-gender-lower-rate-but-same-mortality-of-severe-disease-in-women-an-observational-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/at-the-peak-of-covid-19-age-and-disease-severity-but-not-comorbidities-are-predictors-of-mortality-covid-19-burden-in-bergamo-italy/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/ropeginterferon-alfa-2b-versus-phlebotomy-in-low-risk-patients-with-polycythaemia-vera-low-pv-study-a-multicentre-randomised-phase-2-trial/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/prevalence-and-risk-factors-for-pulmonary-hypertension-associated-with-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/among-classic-myeloproliferative-neoplasms-essential-thrombocythemia-is-associated-with-the-greatest-risk-of-venous-thromboembolism-during-covid-19/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/high-mortality-rate-in-covid-19-patients-with-myeloproliferative-neoplasms-after-abrupt-withdrawal-of-ruxolitinib/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/addressing-key-clinical-care-and-clinical-research-needs-in-severe-pediatric-traumatic-brain-injury-perspectives-from-a-focused-international-conference/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/tolerance-to-bone-marrow-transplantation-do-mesenchymal-stromal-cells-still-have-a-future-for-acute-or-chronic-gvhd/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/the-role-of-complement-in-the-mechanism-of-action-of-therapeutic-anti-cancer-mabs/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/combined-anti-cancer-strategies-based-on-anti-checkpoint-inhibitor-antibodies/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/utility-of-routine-evaluation-of-sterility-of-cellular-therapy-products-with-or-without-extensive-manipulation-best-practices-and-clinical-significance/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/second-cancers-in-mpn-survival-analysis-from-an-international-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/the-new-who-classification-for-essential-thrombocythemia-calls-for-revision-of-available-evidences/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/monoclonal-antibody-monitoring-clinically-relevant-aspects-a-systematic-critical-review/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/integrating-natriuretic-peptides-and-diastolic-dysfunction-to-predict-adverse-events-in-high-risk-asymptomatic-subjects/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/key-features-defining-the-disposition-of-bispecific-antibodies-and-their-efficacy-in-vivo/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/key-features-defining-the-disposition-of-bispecific-antibodies-and-their-efficacy-in-vivo-2/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/arterial-thrombosis-in-philadelphia-negative-myeloproliferative-neoplasms-predicts-second-cancer-a-case-control-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/ruxolitinib-for-the-prevention-of-thrombosis-in-polycythemia-vera-a-systematic-review-and-meta-analysis/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/impact-of-bone-marrow-fibrosis-grade-in-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis-a-study-of-the-mysec-group/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/trend-of-antitissue-transglutaminase-antibody-normalization-in-children-with-celiac-disease-started-on-gluten-free-diet-a-comparative-study-between-chemiluminescence-and-elisa-serum-assays/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/prolonged-qrs-associated-with-left-bundle-branch-conduction-defect-is-a-prognostic-red-flag-in-asymptomatic-patients-at-risk-for-heart-failure-accf-aha-stages-a-and-b-insights-from-the-david-berg/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/leukocytosis-and-thrombosis-in-polycythemia-vera-can-clinical-trials-settle-the-debate/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/risk-stratifying-asymptomatic-left-ventricular-systolic-dysfunction-in-the-community-beyond-left-ventricular-ejection-fraction/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/three-month-mortality-in-permanently-bedridden-medical-non-oncologic-patients-the-beclap-study-permanently-bedridden-creatinine-clearance-albumin-previous-hospital-admissions-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/reply-to-second-primary-malignancies-in-myeloproliferative-neoplasms-and-the-role-of-aspirin/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/eeg-reactivity-predicts-recovery-of-consciousness-in-patients-with-acute-brain-injury-and-signs-of-intracranial-hypertension/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/ontology-driven-real-world-evidence-extraction-from-clinical-narratives/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/addressing-and-proposing-solutions-for-unmet-clinical-needs-in-the-management-of-myeloproliferative-neoplasm-associated-thrombosis-a-consensus-based-position-paper/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/the-importance-of-breathing-not-properly-chronic-obstructive-pulmonary-disease-as-a-risk-factor-for-rehospitalization-in-heart-failure/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/leukocytosis-and-thrombosis-in-essential-thrombocythemia-and-polycythemia-vera-a-systematic-review-and-meta-analysis/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/italian-survey-on-clinical-practice-in-myeloproliferative-neoplasms-a-gimema-myeloproliferative-neoplasms-working-party-initiative/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/second-primary-malignancies-in-postpolycythemia-vera-and-postessential-thrombocythemia-myelofibrosis-a-study-on-2233-patients/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/facing-erythrocytosis-results-of-an-international-physician-survey/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/second-cancer-in-philadelphia-negative-myeloproliferative-neoplasms-mpn-k-a-nested-case-control-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/clinical-outcomes-under-hydroxyurea-treatment-in-polycythemia-vera-a-systematic-review-and-meta-analysis/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/acute-and-subacute-outcome-predictors-in-moderate-and-severe-traumatic-brain-injury-a-retrospective-monocentric-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/emerging-translational-science-discoveries-clonal-approaches-and-treatment-trends-in-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/the-colon-as-an-energy-salvage-organ-for-children-with-short-bowel-syndrome/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/human-neutrophils-express-low-levels-of-fc%ce%b3riiia-which-plays-a-role-in-pmn-activation/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/comments-on-pre-fibrotic-myelofibrosis-and-how-should-it-be-managed/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/different-effect-of-hydroxyurea-and-phlebotomy-on-prevention-of-arterial-and-venous-thrombosis-in-polycythemia-vera/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/hydroxyurea-prevents-arterial-and-late-venous-thrombotic-recurrences-in-patients-with-myeloproliferative-neoplasms-but-fails-in-the-splanchnic-venous-district-pooled-analysis-of-1500-cases/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/targeting-myeloid-cells-to-prevent-recurrent-stroke-in-general-population-the-lesson-of-hydroxyurea-in-myeloproliferative-neoplasms/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/prefibrotic-myelofibrosis-treatment-algorithm-2018/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/polycythemia-vera-and-essential-thrombocythemia-2019-update-on-diagnosis-risk-stratification-and-management/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/response-to-questions-arising-on-phlebotomy-in-polycythemia-vera-prophylactic-measures-to-reduce-thromboembolic-events-require-patient-focused-decisions-by-heidel-et-al/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/gender-effect-on-phenotype-and-genotype-in-patients-with-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis-results-from-the-mysec-project/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/is-mild-asymptomatic-left-ventricular-systolic-dysfunction-always-predictive-of-adverse-events-in-high-risk-populations-insights-from-the-david-berg-study/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/cord-blood-derived-cytokine-induced-killer-cells-combined-with-blinatumomab-as-a-therapeutic-strategy-for-cd19-tumors/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/vanishing-bile-ducts-in-the-long-term-after-pediatric-hematopoietic-stem-cell-transplantation/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/automatic-processing-of-anatomic-pathology-reports-in-the-italian-language-to-enhance-the-reuse-of-clinical-data/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/evidence-and-consensus-based-recommendations-for-phlebotomy-in-polycythemia-vera/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/antithrombotic-therapy-for-venous-thromboembolism-in-myeloproliferative-neoplasms/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/splanchnic-vein-thrombosis-in-myeloproliferative-neoplasms-treatment-algorithm-2018/ 2025-02-18T09:46:10+00:00 https://from.publifarm.com/pubblicazioni/prevalence-and-prognostic-impact-of-non-cardiac-co-morbidities-in-heart-failure-outpatients-with-preserved-and-reduced-ejection-fraction-a-community-based-study/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/clinical-presentation-and-outcome-in-a-contemporary-cohort-of-patients-with-acute-myocarditis-the-multicenter-lombardy-registry/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/thyroid-autoantibodies-and-the-clinical-presentation-of-moyamoya-disease-a-prospective-study/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/phenotype-variability-of-patients-with-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis-is-associated-with-the-time-to-progression-from-polycythemia-vera-and-essential-thrombocy/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/innovative-haematological-parameters-for-early-diagnosis-of-sepsis-in-adult-patients-admitted-in-intensive-care-unit/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/recent-advances-in-the-genomics-and-therapy-of-bcr-abl1-positive-and-negative-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/value-of-cytogenetic-abnormalities-in-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis-a-study-of-the-mysec-project/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/philadelphia-chromosome-negative-classical-myeloproliferative-neoplasms-revised-management-recommendations-from-european-leukemianet/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/the-2016-who-classification-and-diagnostic-criteria-for-myeloproliferative-neoplasms-document-summary-and-in-depth-discussion/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/benefit-risk-profile-of-cytoreductive-drugs-along-with-antiplatelet-and-antithrombotic-therapy-after-transient-ischemic-attack-or-ischemic-stroke-in-myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/mipss70-mutation-enhanced-international-prognostic-score-system-for-transplantation-age-patients-with-primary-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/lymphoproliferative-disorders-in-patients-with-chronic-myeloproliferative-neoplasms-a-systematic-review/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/polycythemia-vera-treatment-algorithm-2018/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/incidence-of-solid-tumors-in-polycythemia-vera-treated-with-phlebotomy-with-or-without-hydroxyurea-eclap-follow-up-data/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/essential-thrombocythemia-treatment-algorithm-2018/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/a-clinical-molecular-prognostic-model-to-predict-survival-in-patients-with-post-polycythemia-vera-and-post-essential-thrombocythemia-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/strategy-to-identify-subjects-with-diabetes-mellitus-more-suitable-for-selective-echocardiographic-screening-the-david-berg-study/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/trauma-patients-centralization-for-the-mechanism-of-trauma-old-questions-without-answers/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/prospective-assessment-of-the-agreement-of-instruments-for-measuring-the-hospital-nursing-workload-the-swiss-method-the-karnofsky-performance-status-scale-and-the-subjective-perception-of-the-nurses/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/the-specific-bruton-tyrosine-kinase-inhibitor-acalabrutinib-acp-196-shows-favorable-in-vitro-activity-against-chronic-lymphocytic-leukemia-b-cells-with-cd20-antibodies/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-polycythemia-vera-or-essential-thrombocythemia-transformed-to-myelofibrosis-or-acute-myeloid-leukemia-a-report-from-the-mpn-subcomm/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/a-reappraisal-of-the-benefit-risk-profile-of-hydroxyurea-in-polycythemia-vera-a-propensity-matched-study/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/essential-thrombocythaemia/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/no-correlation-of-intensity-of-phlebotomy-regimen-with-risk-of-thrombosis-in-polycythemia-vera-evidence-from-european-collaboration-on-low-dose-aspirin-in-polycythemia-vera-and-cytoreductive-therapy/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/presentation-and-outcome-of-patients-with-2016-who-diagnosis-of-prefibrotic-and-overt-primary-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/primary-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/polycythaemia-vera/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/diagnostic-impact-of-the-2016-revised-who-criteria-for-polycythemia-vera/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/echocardiographic-outflow-pump-ramp-test-in-centrifugal-flow-left-ventricular-assist-device/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/ace-inhibitors-and-cytoreductive-therapy-in-polycythemia-vera/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/grey-zones-in-cardiomyopathies-defining-boundaries-between-genetic-and-iatrogenic-disease/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/the-effect-of-arterial-hypertension-on-thrombosis-in-low-risk-polycythemia-vera/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/splanchnic-vein-thrombosis-in-myeloproliferative-neoplasms-risk-factors-for-recurrences-in-a-cohort-of-181-patients/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/overview-of-diagnostic-performance-and-results-for-the-first-operation-phase-in-wendelstein-7-x-invited/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/the-2016-revision-of-who-classification-of-myeloproliferative-neoplasms-clinical-and-molecular-advances/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/effect-of-anakinra-on-recurrent-pericarditis-among-patients-with-colchicine-resistance-and-corticosteroid-dependence-the-airtrip-randomized-clinical-trial/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/high-rate-of-recurrent-venous-thromboembolism-in-patients-with-myeloproliferative-neoplasms-and-effect-of-prophylaxis-with-vitamin-k-antagonists/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/prognostic-impact-of-bone-marrow-fibrosis-in-primary-myelofibrosis-a-study-of-the-agimm-group-on-490-patients/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/long-term-findings-from-comfort-ii-a-phase-3-study-of-ruxolitinib-vs-best-available-therapy-for-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/contemporary-insights-into-the-pathogenesis-and-treatment-of-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/epidemiology-and-clinical-relevance-of-mutations-in-postpolycythemia-vera-and-postessential-thrombocythemia-myelofibrosis-a-study-on-359-patients-of-the-agimm-group/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/refining-prognostication-of-thrombosis-in-et/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/myeloproliferative-neoplasms-morphology-and-clinical-practice/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/myeloproliferative-neoplasms-and-inflammation-whether-to-target-the-malignant-clone-or-the-inflammatory-process-or-both/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/molecular-biomarkers-of-thrombosis-in-myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/role-of-biomarkers-in-cardiac-structure-phenotyping-of-heart-failure-with-preserved-ejection-fraction-critical-appraisal-and-practical-use/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/indication-and-management-of-allogeneic-stem-cell-transplantation-in-primary-myelofibrosis-a-consensus-process-by-an-ebmt-eln-international-working-group/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/essential-thrombocythemia-and-polycythemia-vera-focus-on-clinical-practice/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/esmo-guidelines-committee-philadelphia-chromosome-negative-chronic-myeloproliferative-neoplasms-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/new-and-treatment-relevant-risk-stratification-for-thrombosis-in-essential-thrombocythemia-and-polycythemia-vera/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/heart-failure-at-crossroads-moving-beyond-blaming-stakeholders-to-targeting-the-heart/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/white-blood-cell-counts-and-thrombosis-in-polycythemia-vera-a-subanalysis-of-the-cyto-pv-study/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/novel-insights-into-the-biology-and-treatment-of-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/patterns-of-presentation-and-thrombosis-outcome-in-patients-with-polycythemia-vera-strictly-defined-by-who-criteria-and-stratified-by-calendar-period-of-diagnosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/calr-mutation-mpl-mutation-and-triple-negativity-identify-patients-with-the-lowest-vascular-risk-in-primary-myelofibrosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/the-rate-of-transformation-from-jak2-mutated-et-to-pv-is-influenced-by-an-accurate-who-defined-clinico-morphological-diagnosis/ 2025-02-18T09:46:11+00:00 https://from.publifarm.com/pubblicazioni/immunohistochemistry-is-highly-sensitive-and-specific-for-the-detection-of-nrasq61r-mutation-in-melanoma/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/associazione-italiana-per-la-ricerca-sul-cancro-gruppo-italiano-malattie-mieloproliferative-agimm-investigators-abnormal-expression-patterns-of-wt1-as-meg3-and-anril-long-non-coding-rnas-in-cd34/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/polycythemia-vera-and-essential-thrombocythemia-2015-update-on-diagnosis-risk-stratification-and-management/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/perioperative-management-of-oral-antiplatelet-therapy-and-clinical-outcomes-in-coronary-stent-patients-undergoing-surgery-results-of-a-multicentre-registry/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/clinical-end-points-for-drug-treatment-trials-in-bcr-abl1-negative-classic-myeloproliferative-neoplasms-consensus-statements-from-european-leukemianet-eln-and-internation-working-group-myeloprolife/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/prognostic-scores-in-heart-failure-critical-appraisal-and-practical-use/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/palliative-needs-for-heart-failure-or-chronic-obstructive-pulmonary-disease-results-of-a-multicenter-observational-registry/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/towards-a-better-understanding-of-epidemiology-survival-and-treatment-in-myeloproliferative-neoplasms-results-of-the-european-leukemianet-registry-ernest-study/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/pd-l1-marks-a-subset-of-melanomas-with-a-shorter-overall-survival-and-distinct-genetic-and-morphological-characteristics/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/myeloblative-therapy-with-autologous-haematopoietic-stem-cell-support-as-consolidation-of-first-remission-in-acute-myeloid-leukaemia-very-long-follow-up/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/in-contemporary-patients-with-polycythemia-vera-rates-of-thrombosis-and-risk-factors-delineate-a-new-clinical-epidemiology/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/a-lower-intensity-of-treatment-may-underlie-the-increased-risk-of-thrombosis-in-young-patients-with-masked-polycythaemia-vera/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/cerebral-vein-thrombosis-in-patients-with-philadelphia-negative-myeloproliferative-neoplasms-an-european-leukemia-net-study/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/new-strategies-for-heart-failure-with-preserved-ejection-fraction-the-importance-of-targeted-therapies-for-heart-failure-phenotypes/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/calreticulin-mutation-does-not-modify-the-ipset-score-for-predicting-the-risk-of-thrombosis-among-1150-patients-with-essential-thrombocythemia/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/long-term-survival-and-blast-transformation-in-molecularly-annotated-essential-thrombocythemia-polycythemia-vera-and-myelofibrosis/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/essential-thrombocythemia-with-high-hemoglobin-levels-according-to-the-revised-who-classification/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/associazione-italiana-per-la-ricerca-sul-cancro-gruppo-italiano-malattie-mieloproliferative-investigators-clinical-effect-of-driver-mutations-of-jak2-calr-or-mpl-in-primary-myelofibrosis/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/cancer-survivorship-programs-time-for-concerted-action/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/an-overview-on-calr-and-csf3r-mutations-and-a-proposal-for-revision-of-who-diagnostic-criteria-for-myeloproliferative-neoplasms/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/distinct-clustering-of-symptomatic-burden-among-myeloproliferative-neoplasm-patients-retrospective-assessment-in-1470-patients/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/discriminating-between-essential-thrombocythemia-and-masked-polycythemia-vera-in-jak2-mutated-patients/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/rethinking-the-diagnostic-criteria-of-polycythemia-vera/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/current-pre-clinical-and-clinical-advances-in-the-bcr-abl1-positive-and-negative-chronic-myeloproliferative-neoplasms/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/investigators-of-the-italian-study-on-endocarditis-predicting-the-occurrence-of-embolic-events-an-analysis-of-1456-episodes-of-infective-endocarditis-from-the-italian-study-on-endocarditis-sei/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/impact-of-ruxolitinib-on-the-natural-history-of-primary-myelofibrosis-a-comparison-of-the-dipss-and-the-comfort-2-cohorts/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/pregnancy-complications-predict-thrombotic-events-in-young-women-with-essential-thrombocythemia/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/a-phase-2-study-of-ruxolitinib-an-oral-jak1-and-jak2-inhibitor-in-patients-with-advanced-polycythemia-vera-who-are-refractory-or-intolerant-to-hydroxyurea/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/masked-polycythemia-vera-diagnosed-according-to-who-and-bcsh-classification/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/identifying-and-addressing-unmet-clinical-needs-in-ph-neg-classical-myeloproliferative-neoplasms-a-consensus-based-sie-sies-gitmo-position-paper/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/comparison-of-placebo-and-best-available-therapy-for-the-treatment-of-myelofibrosis-in-the-phase-3-comfort-studies/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/masked-polycythemia-vera-mpv-results-of-an-international-study/ 2025-02-18T09:46:12+00:00 https://from.publifarm.com/pubblicazioni/on-the-behalf-of-the-in-hf-outcome-investigators-in-hospital-and-1-year-outcomes-of-acute-heart-failure-patients-according-to-presentation-de-novo-vs-worsening-and-ejection-fraction-results-from/ 2025-02-18T09:46:12+00:00